GABRP and neoplasm: However, challenges still exist: There are many subtypes of the GABA receptor family, and inhibitor selectivity needs to be optimized to avoid central nervous system side effects; Tumor heterogeneity may lead to differences in GABRP dependence, and biomarkers (such as GABRP+/PD‐L1+ double‐positive subgroups) need to be developed to screen the beneficiary population; The bioavailability and delivery efficiency of amentoflavone need to be improved (such as nanoliposome encapsulation).